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Evidence Based Medicine
Can Selective Serotonin Reuptake Inhibitors (SSRI) improve motor
recovery after stroke? What is the role of Neuroplasticity?
Farzin Majeed, Ayeesha Kamran Kamal
Stroke Service and Vascular Fellowship Program, International Cerebrovascular Translational Clinical Research Training Program (Fogarty International
Center and National Institute of Neurologic Disorders and Stroke), Aga Khan University Hospital, Karachi, Pakistan.

What is neuronal plasticity?
Neuronal plasticity or Neuroplasticity refers to the
ability of the brain to change as a result of one's experience.
It is basically a flexible property of the neurons or neuronal
networks to change their physiological and morphological
characteristics and adapt to new situations arising from
environmental situations like trauma or stroke.

Why is this concept important? What was
tested in the FLAME study?
The lifetime prevalence of stroke in Pakistan as quoted
by a recent community based study is 19% which is
dramatically high. Approximately two thirds of these stroke
survivors have residual neurological deficits. At the present
time, only tissue plasminogen activator (tPA) is approved for
use in the management of acute ischaemic stroke in an attempt
to reduce the severity of brain damage. However, the use of tPA
is limited due to several factors, including the narrow time
window over which it must be used, delays in diagnosis,
misdiagnosis, cost constraints or fear of adverse side effects.
Therefore more attention needs to be focused on alternative
strategies to reduce the long-term disability and functional
impairment after stroke, probably by enhancing brain plasticity.
The aim of a new study called "FLAME" (Acronym for
- Fluoxetine for Motor Recovery After Acute Ischaemic
Stroke) was to investigate if fluoxetine was capable of
enhancing motor recovery, when given soon after an ischaemic
stroke to patients who have moderate to severe motor deficits.
This is because earlier clinical trials have suggested
that fluoxetine (a drug used in the treatment of depression,
obsessive-compulsive disorders) enhances motor recovery by
increasing serotonergic transmission, formation of new
synaptic contacts and cortical over-stimulation but its clinical
efficacy was still unknown.

Who were the participants? What was the
Intervention?
Patients with acute ischaemic stroke causing
hemiplegia or hemiparesis were prospectively enrolled from
9 stroke units in France. They were mostly between 60-66
years of age. Most of them had cortical (anterior circulation)
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infarcts and moderate to severe disability as measured by
MRS. Both the intervention arm (fluoxetine 20mg PO daily
for 3 months) and the placebo arm were well matched for
their risk factor profile, demographics and stroke
severity.However, patients with severe post-stroke disability
and clinically diagnosed depression were excluded.
All patients received standard physiotherapy.

What were the findings?
A total of 118 patients were randomly assigned to
fluoxetine (n=59) or placebo (n=59), and 113 were included
in the analysis (57 in the fluoxetine group and 56 in the
placebo group). Two patients died even before day 90 and
three withdrew themselves from the study.The results showed
that the Fugl-Meyer motor scale (FMMS) improvement at
day 90 was significantly greater in the fluoxetine group than
in the placebo group (an improvement of 36 vs 24 points).
The mRS scores showed more independent patients
(scores 0-2) in the fluoxetine group than in the placebo
group at day 90.Occurrence of depression during the 3
months was significantly lower in the fluoxetine group than
in the placebo group.

What were the conclusions?
The study revealed that in patients with ischaemic
stroke and motor deficits, the early prescription of fluoxetine
along with physiotherapy helped in enhancing the motor
recovery over a period of 3 months. The authors also
concluded that early use of Fluoxetine also prevents against
post-stroke depression, which is another important cause of
functional debility after stroke. This is the first largest
randomized placebo controlled trial to show that treatment
with an SSRI is associated with improved motor recovery
after an acute ischaemic stroke. This study provides new
information regarding the role of fluoxetine in plasticity,
neurogenesis, and neuronal differentiation. It has identified
the superiority of fluoxetine over placebo in improving
functional recovery in stroke patients , independent of its
effects on depression.

How can this study effect our clinical practice?
Stroke survivors and their families often find it
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difficult to manage this long-term condition given the abrupt
transition from being "healthy" to having disability. The
situation is further exacerbated by the lack of communitybased programmes and rehabilitation services that may help
survivors reduce the risk of recurrent events and improve
quality of life. At present, most patients with ischaemic stroke
are not given antidepressant drugs unless they show
appreciable symptoms of depression. This study has provided
useful evidence regarding the role of fluoxetine in
neuroplasticity, particularly when it is started in the acute
phase of stroke, thereby helping motor recovery.
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